YVN Summary
\n\nDrug companies would have to tell the patent office and the FDA the same facts about their medicines. Right now, federal drug law does not require those two accounts to match. The rule covers brand-name drugs and biological products (medicines made from living cells). Companies would also have to send the patent office what they tell the FDA about a patent, plus the FDA's replies.\n\nIt applies to new drug applications filed after the law takes effect. For drugs already in the pipeline, it covers only new patents and new filings after that date. Most people would see no direct change in what they pay. The bill's name points to drug prices, but the text sets no price limit or cost rule.\n\nA company that skips its FDA patent statement would break federal drug law. A company sued for copying a patented drug could also fight back in court. It could argue the patent owner carelessly or on purpose held back facts it had to share. Firms tied to China, Russia, Iran, North Korea, Cuba, or Maduro's Venezuela could not use that defense. Shared data would stay protected as trade secrets. The patent office could still release facts the public needs to understand what a patent covers.
","status":"FLOOR_CONSIDERATION","topics":["HEALTHCARE"],"introducedAt":"2025-08-01T00:00:00+00:00","latestActionAt":"2026-07-28T00:00:00+00:00","congressGovUrl":"https://www.congress.gov/bill/119th-congress/senate-bill/2658","accountabilityFlags":{"corporate_benefits":["↓ Drug patent owners' lawsuits — can fail if required facts were hidden","↓ Firms tied to China, Russia, Iran — barred from new patent defense"],"transparency_accountability":["↑ Drugmakers' patent claims — must match what they tell the FDA","↑ Drugmakers' patent facts given to FDA — shared with patent office","↑ Skipping the FDA patent statement — becomes a drug law violation","↑ Public view of drug patents — patent office may release some data"]},"tldr":"Drug firms would have to tell the FDA and the patent office the same facts — or risk losing patent suits.","summaryStandard":"v2","flagExplainers":{"corporate_benefits":["A new rule in patent law would give a company sued over a drug patent a way to fight back. It would work if the patent owner, or a past owner, failed to share the facts it had to. That failure can be careless or on purpose.","The committee added a limit. Firms tied to six named nations could not use the new defense. They are China, Russia, Iran, North Korea, Cuba, and Venezuela under Maduro. A U.S. security law already lists which firms count."],"transparency_accountability":["A company that wants FDA approval would have to state that, as far as it knows, its patent facts match what it told the patent office. It would also tell the patent office its filing there is full and matches what the FDA saw.","Facts that bear on whether a drug deserves a patent, and that a company gives the FDA, would also go to the patent office. So would the FDA's answers. This covers lab data on how a drug is made and claims about earlier inventions.","Failing to file the statement to the FDA would be added to the list of banned acts in federal drug law. The bill does not make the patent-office statement part of that list.","Data sent to the patent office would stay as secret as it is at the FDA. The committee added one catch. The patent office may share facts the public needs to see what a patent covers."]},"flagValence":{"corporate_benefits":["contested","contested"],"transparency_accountability":["good","good","good","contested"]},"needsResummary":false,"displaySummaryHtml":null,"rawStatusText":"Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.","chamber":"SENATE","policyArea":"Health","legislativeSubjects":["Drug safety, medical device, and laboratory regulation","Inflation and prices","Intellectual property","Manufacturing","Prescription drugs"],"lawStatus":null,"lawNumber":null,"latestActionText":"Placed on Senate Legislative Calendar under General Orders. Calendar No. 528.","latestTextVersion":"Reported to Senate","textVersionUsed":null,"dateAdded":"2026-10-20T00:00:00+00:00","summarizedAt":"2026-10-23T18:17:56+00:00","recordId":"a03a3313-2174-4c25-aff5-e21e572b8cd2","feedIdentityKey":"119/s/2658","websiteBillId":"S-2658","yourvoiceSummary":"Drug companies would have to tell the patent office and the FDA the same facts about their medicines. Right now, federal drug law does not require those two accounts to match. The rule covers brand-name drugs and biological products (medicines made from living cells). Companies would also have to send the patent office what they tell the FDA about a patent, plus the FDA's replies.\n\nIt applies to new drug applications filed after the law takes effect. For drugs already in the pipeline, it covers only new patents and new filings after that date. Most people would see no direct change in what they pay. The bill's name points to drug prices, but the text sets no price limit or cost rule.\n\nA company that skips its FDA patent statement would break federal drug law. A company sued for copying a patented drug could also fight back in court. It could argue the patent owner carelessly or on purpose held back facts it had to share. Firms tied to China, Russia, Iran, North Korea, Cuba, or Maduro's Venezuela could not use that defense. Shared data would stay protected as trade secrets. The patent office could still release facts the public needs to understand what a patent covers.","updatedAt":"2026-10-25T04:22:04.770845+00:00"}